Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FEC followed by Paclitaxel and Trastuzumab in HER2+ Breast Cancer
NCT01340430Phase 2Completed
- Start
- Mar 2011
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in breast cancer. Started Mar 2011; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01340430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340430.